GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

The approval broadens the previous indication for Jemperli plus chemotherapy in ... The company says RUBY Part 1 is the only clinical trial in this setting to show a clinically meaningful and ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for at least 30 days ...

Both the EC and FDA approvals draw on data from the DUO-E trial, published in the Journal of Clinical Oncology ... Lynparza pitted against the GSK's Jemperli (dostarlimab) and MSD's Keytruda ...

IDRX-42 adds to GSK’s existing gastrointestinal cancer programmes, which include ongoing clinical trials with checkpoint inhibitor Jemperli (dostarlimab) and the B7-H3-targeted antibody-drug ...

Other antibodies in its portfolio include ANB033, an anti-CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, soon to enter clinical ... PD-1 antagonist (Jemperli (dostarlimab ...

Jemperli’s was approved for the first-line ... a quick chat with the Grove.AI team about their new AI agent for clinical trial recruitment. AstraZeneca has become the first company to get ...

Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...

The European Commission has approved Jemperli (dostarlimab ... commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents ...